Medical Care

Global Peptide-Drug Conjugates Market Research Report 2025

The global market for Peptide-Drug Conjugates was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Peptide-Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-Drug Conjugates.
The Peptide-Drug Conjugates market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide-Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide-Drug Conjugates companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Bicycle Therapeutics
Cybrexa Therapeutics
Esperance Pharmaceuticals
Oncopeptides
Pepgen Corporation
Soricimed Biopharma
Theratechnologies
Segment by Type
Cell-penetrating Peptides (CPPs)
Cell-targeting Peptides (CTPs)
Segment by Application
Carcinoma
Sarcoma
Melanoma
Lymphoma
Leukemia
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide-Drug Conjugates company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide-Drug Conjugates Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cell-penetrating Peptides (CPPs)
1.2.3 Cell-targeting Peptides (CTPs)
1.3 Market by Application
1.3.1 Global Peptide-Drug Conjugates Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Carcinoma
1.3.3 Sarcoma
1.3.4 Melanoma
1.3.5 Lymphoma
1.3.6 Leukemia
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide-Drug Conjugates Market Perspective (2020-2031)
2.2 Global Peptide-Drug Conjugates Growth Trends by Region
2.2.1 Global Peptide-Drug Conjugates Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide-Drug Conjugates Historic Market Size by Region (2020-2025)
2.2.3 Peptide-Drug Conjugates Forecasted Market Size by Region (2026-2031)
2.3 Peptide-Drug Conjugates Market Dynamics
2.3.1 Peptide-Drug Conjugates Industry Trends
2.3.2 Peptide-Drug Conjugates Market Drivers
2.3.3 Peptide-Drug Conjugates Market Challenges
2.3.4 Peptide-Drug Conjugates Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide-Drug Conjugates Players by Revenue
3.1.1 Global Top Peptide-Drug Conjugates Players by Revenue (2020-2025)
3.1.2 Global Peptide-Drug Conjugates Revenue Market Share by Players (2020-2025)
3.2 Global Peptide-Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide-Drug Conjugates Revenue
3.4 Global Peptide-Drug Conjugates Market Concentration Ratio
3.4.1 Global Peptide-Drug Conjugates Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide-Drug Conjugates Revenue in 2024
3.5 Global Key Players of Peptide-Drug Conjugates Head office and Area Served
3.6 Global Key Players of Peptide-Drug Conjugates, Product and Application
3.7 Global Key Players of Peptide-Drug Conjugates, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide-Drug Conjugates Breakdown Data by Type
4.1 Global Peptide-Drug Conjugates Historic Market Size by Type (2020-2025)
4.2 Global Peptide-Drug Conjugates Forecasted Market Size by Type (2026-2031)
5 Peptide-Drug Conjugates Breakdown Data by Application
5.1 Global Peptide-Drug Conjugates Historic Market Size by Application (2020-2025)
5.2 Global Peptide-Drug Conjugates Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide-Drug Conjugates Market Size (2020-2031)
6.2 North America Peptide-Drug Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide-Drug Conjugates Market Size by Country (2020-2025)
6.4 North America Peptide-Drug Conjugates Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide-Drug Conjugates Market Size (2020-2031)
7.2 Europe Peptide-Drug Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide-Drug Conjugates Market Size by Country (2020-2025)
7.4 Europe Peptide-Drug Conjugates Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide-Drug Conjugates Market Size (2020-2031)
8.2 Asia-Pacific Peptide-Drug Conjugates Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide-Drug Conjugates Market Size (2020-2031)
9.2 Latin America Peptide-Drug Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide-Drug Conjugates Market Size by Country (2020-2025)
9.4 Latin America Peptide-Drug Conjugates Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide-Drug Conjugates Market Size (2020-2031)
10.2 Middle East & Africa Peptide-Drug Conjugates Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Peptide-Drug Conjugates Introduction
11.1.4 AstraZeneca Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.1.5 AstraZeneca Recent Development
11.2 Bicycle Therapeutics
11.2.1 Bicycle Therapeutics Company Details
11.2.2 Bicycle Therapeutics Business Overview
11.2.3 Bicycle Therapeutics Peptide-Drug Conjugates Introduction
11.2.4 Bicycle Therapeutics Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.2.5 Bicycle Therapeutics Recent Development
11.3 Cybrexa Therapeutics
11.3.1 Cybrexa Therapeutics Company Details
11.3.2 Cybrexa Therapeutics Business Overview
11.3.3 Cybrexa Therapeutics Peptide-Drug Conjugates Introduction
11.3.4 Cybrexa Therapeutics Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.3.5 Cybrexa Therapeutics Recent Development
11.4 Esperance Pharmaceuticals
11.4.1 Esperance Pharmaceuticals Company Details
11.4.2 Esperance Pharmaceuticals Business Overview
11.4.3 Esperance Pharmaceuticals Peptide-Drug Conjugates Introduction
11.4.4 Esperance Pharmaceuticals Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.4.5 Esperance Pharmaceuticals Recent Development
11.5 Oncopeptides
11.5.1 Oncopeptides Company Details
11.5.2 Oncopeptides Business Overview
11.5.3 Oncopeptides Peptide-Drug Conjugates Introduction
11.5.4 Oncopeptides Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.5.5 Oncopeptides Recent Development
11.6 Pepgen Corporation
11.6.1 Pepgen Corporation Company Details
11.6.2 Pepgen Corporation Business Overview
11.6.3 Pepgen Corporation Peptide-Drug Conjugates Introduction
11.6.4 Pepgen Corporation Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.6.5 Pepgen Corporation Recent Development
11.7 Soricimed Biopharma
11.7.1 Soricimed Biopharma Company Details
11.7.2 Soricimed Biopharma Business Overview
11.7.3 Soricimed Biopharma Peptide-Drug Conjugates Introduction
11.7.4 Soricimed Biopharma Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.7.5 Soricimed Biopharma Recent Development
11.8 Theratechnologies
11.8.1 Theratechnologies Company Details
11.8.2 Theratechnologies Business Overview
11.8.3 Theratechnologies Peptide-Drug Conjugates Introduction
11.8.4 Theratechnologies Revenue in Peptide-Drug Conjugates Business (2020-2025)
11.8.5 Theratechnologies Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Peptide-Drug Conjugates Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Cell-penetrating Peptides (CPPs)
Table 3. Key Players of Cell-targeting Peptides (CTPs)
Table 4. Global Peptide-Drug Conjugates Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Peptide-Drug Conjugates Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peptide-Drug Conjugates Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Peptide-Drug Conjugates Market Share by Region (2020-2025)
Table 8. Global Peptide-Drug Conjugates Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Peptide-Drug Conjugates Market Share by Region (2026-2031)
Table 10. Peptide-Drug Conjugates Market Trends
Table 11. Peptide-Drug Conjugates Market Drivers
Table 12. Peptide-Drug Conjugates Market Challenges
Table 13. Peptide-Drug Conjugates Market Restraints
Table 14. Global Peptide-Drug Conjugates Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Peptide-Drug Conjugates Market Share by Players (2020-2025)
Table 16. Global Top Peptide-Drug Conjugates Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2024)
Table 17. Ranking of Global Top Peptide-Drug Conjugates Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Peptide-Drug Conjugates Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Peptide-Drug Conjugates, Headquarters and Area Served
Table 20. Global Key Players of Peptide-Drug Conjugates, Product and Application
Table 21. Global Key Players of Peptide-Drug Conjugates, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Peptide-Drug Conjugates Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Peptide-Drug Conjugates Revenue Market Share by Type (2020-2025)
Table 25. Global Peptide-Drug Conjugates Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Peptide-Drug Conjugates Revenue Market Share by Type (2026-2031)
Table 27. Global Peptide-Drug Conjugates Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Peptide-Drug Conjugates Revenue Market Share by Application (2020-2025)
Table 29. Global Peptide-Drug Conjugates Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Peptide-Drug Conjugates Revenue Market Share by Application (2026-2031)
Table 31. North America Peptide-Drug Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Peptide-Drug Conjugates Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Peptide-Drug Conjugates Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Peptide-Drug Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Peptide-Drug Conjugates Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Peptide-Drug Conjugates Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Peptide-Drug Conjugates Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Peptide-Drug Conjugates Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Peptide-Drug Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Peptide-Drug Conjugates Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Peptide-Drug Conjugates Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Peptide-Drug Conjugates Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Peptide-Drug Conjugates Market Size by Country (2026-2031) & (US$ Million)
Table 46. AstraZeneca Company Details
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca Peptide-Drug Conjugates Product
Table 49. AstraZeneca Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Bicycle Therapeutics Company Details
Table 52. Bicycle Therapeutics Business Overview
Table 53. Bicycle Therapeutics Peptide-Drug Conjugates Product
Table 54. Bicycle Therapeutics Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 55. Bicycle Therapeutics Recent Development
Table 56. Cybrexa Therapeutics Company Details
Table 57. Cybrexa Therapeutics Business Overview
Table 58. Cybrexa Therapeutics Peptide-Drug Conjugates Product
Table 59. Cybrexa Therapeutics Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 60. Cybrexa Therapeutics Recent Development
Table 61. Esperance Pharmaceuticals Company Details
Table 62. Esperance Pharmaceuticals Business Overview
Table 63. Esperance Pharmaceuticals Peptide-Drug Conjugates Product
Table 64. Esperance Pharmaceuticals Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 65. Esperance Pharmaceuticals Recent Development
Table 66. Oncopeptides Company Details
Table 67. Oncopeptides Business Overview
Table 68. Oncopeptides Peptide-Drug Conjugates Product
Table 69. Oncopeptides Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 70. Oncopeptides Recent Development
Table 71. Pepgen Corporation Company Details
Table 72. Pepgen Corporation Business Overview
Table 73. Pepgen Corporation Peptide-Drug Conjugates Product
Table 74. Pepgen Corporation Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 75. Pepgen Corporation Recent Development
Table 76. Soricimed Biopharma Company Details
Table 77. Soricimed Biopharma Business Overview
Table 78. Soricimed Biopharma Peptide-Drug Conjugates Product
Table 79. Soricimed Biopharma Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 80. Soricimed Biopharma Recent Development
Table 81. Theratechnologies Company Details
Table 82. Theratechnologies Business Overview
Table 83. Theratechnologies Peptide-Drug Conjugates Product
Table 84. Theratechnologies Revenue in Peptide-Drug Conjugates Business (2020-2025) & (US$ Million)
Table 85. Theratechnologies Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
Table 89. Authors List of This Report


List of Figures
Figure 1. Peptide-Drug Conjugates Picture
Figure 2. Global Peptide-Drug Conjugates Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peptide-Drug Conjugates Market Share by Type: 2024 VS 2031
Figure 4. Cell-penetrating Peptides (CPPs) Features
Figure 5. Cell-targeting Peptides (CTPs) Features
Figure 6. Global Peptide-Drug Conjugates Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Peptide-Drug Conjugates Market Share by Application: 2024 VS 2031
Figure 8. Carcinoma Case Studies
Figure 9. Sarcoma Case Studies
Figure 10. Melanoma Case Studies
Figure 11. Lymphoma Case Studies
Figure 12. Leukemia Case Studies
Figure 13. Peptide-Drug Conjugates Report Years Considered
Figure 14. Global Peptide-Drug Conjugates Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Peptide-Drug Conjugates Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Peptide-Drug Conjugates Market Share by Region: 2024 VS 2031
Figure 17. Global Peptide-Drug Conjugates Market Share by Players in 2024
Figure 18. Global Top Peptide-Drug Conjugates Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Drug Conjugates as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Peptide-Drug Conjugates Revenue in 2024
Figure 20. North America Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Peptide-Drug Conjugates Market Share by Country (2020-2031)
Figure 22. United States Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Peptide-Drug Conjugates Market Share by Country (2020-2031)
Figure 26. Germany Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Peptide-Drug Conjugates Market Share by Region (2020-2031)
Figure 34. China Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Peptide-Drug Conjugates Market Share by Country (2020-2031)
Figure 42. Mexico Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Peptide-Drug Conjugates Market Share by Country (2020-2031)
Figure 46. Turkey Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Peptide-Drug Conjugates Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AstraZeneca Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 50. Bicycle Therapeutics Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 51. Cybrexa Therapeutics Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 52. Esperance Pharmaceuticals Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 53. Oncopeptides Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 54. Pepgen Corporation Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 55. Soricimed Biopharma Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 56. Theratechnologies Revenue Growth Rate in Peptide-Drug Conjugates Business (2020-2025)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies